Relay Therapeutics (NASDAQ:RLAY) Stock: Insider Thomas Catinazzo Sells 32,717 Shares

Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Free Report) CFO Thomas Catinazzo sold 32,717 shares of the company’s stock in a transaction on Wednesday, November 18th. The shares were sold at an average price of $16.51, for a total value of $540,157.67. Following the completion of the sale, the chief financial officer owned 70,948 shares in the company, valued at $1,171,351.48. This represents a 31.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Thomas Catinazzo also recently made the following trade(s):

  • On Wednesday, October 28th, Thomas Catinazzo sold 1,469 shares of Relay Therapeutics stock. The shares were sold at an average price of $18.62, for a total value of $27,352.78.
  • On Tuesday, October 6th, Thomas Catinazzo sold 17,717 shares of Relay Therapeutics stock. The stock was sold at an average price of $18.59, for a total value of $329,359.03.
  • On Tuesday, September 8th, Thomas Catinazzo sold 17,717 shares of Relay Therapeutics stock. The stock was sold at an average price of $18.94, for a total value of $335,559.98.

Relay Therapeutics Stock Performance

RLAY stock traded up $0.20 during trading on Friday, hitting $16.11. The stock had a trading volume of 3,974,822 shares, compared to its average volume of 3,111,643. The company’s 50 day moving average price is $18.18 and its two-hundred day moving average price is $15.66. Relay Therapeutics, Inc. has a 1-year low of $6.28 and a 1-year high of $21.27. The stock has a market cap of $3.56 billion, a price-to-earnings ratio of -10.67 and a beta of 1.74.

Relay Therapeutics (NASDAQ:RLAY – Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.03. As a group, sell-side analysts forecast that Relay Therapeutics, Inc. will post -1.58 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in RLAY. American Century Companies Inc. raised its holdings in shares of Relay Therapeutics by 94.7% in the 3rd quarter. American Century Companies Inc. now owns 80,034 shares of the company’s stock worth $1,445,000 after purchasing an additional 38,933 shares during the period. New York State Common Retirement Fund grew its holdings in shares of Relay Therapeutics by 7.1% during the 3rd quarter. New York State Common Retirement Fund now owns 63,099 shares of the company’s stock worth $1,139,000 after purchasing an additional 4,164 shares during the period. Jump Financial LLC acquired a new stake in Relay Therapeutics during the 3rd quarter worth approximately $6,021,000. Marshall Wace LLP increased its position in Relay Therapeutics by 77.1% during the 3rd quarter. Marshall Wace LLP now owns 31,600 shares of the company’s stock worth $570,000 after purchasing an additional 13,757 shares in the last quarter. Finally, Mayport LLC purchased a new position in Relay Therapeutics in the third quarter valued at approximately $897,000. 96.98% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on RLAY. Barclays upped their price objective on shares of Relay Therapeutics from $27.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. HC Wainwright lifted their price objective on Relay Therapeutics from $28.00 to $29.00 and gave the company a “buy” rating in a research report on Thursday, August 20th. Guggenheim reiterated a “buy” rating on shares of Relay Therapeutics in a research note on Friday, August 7th. Citizens Jmp increased their target price on Relay Therapeutics from $21.00 to $26.00 and gave the stock a “market outperform” rating in a research report on Monday, August 10th. Finally, JonesTrading raised their price target on Relay Therapeutics from $20.00 to $31.00 and gave the stock a “buy” rating in a research note on Friday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $27.00.

Read Our Latest Report on RLAY

About Relay Therapeutics

(Get Free Report)

Relay Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing medicines for patients with serious diseases, with an emphasis on cancer. The company uses its computational drug discovery platform to study how proteins move and interact, aiming to identify drug targets and design therapies against them. Relay’s research combines experimental biology, structural biology and computational methods. Its drug development programs have included candidates targeting cancer-related pathways, such as FGFR2 and PI3Kα.

Read More

Insider Buying and Selling by Quarter for Relay Therapeutics (NASDAQ:RLAY)

Receive News & Ratings for Relay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.